Dutasteride 0.3% | Minoxidil 8%

Route: Topical scalp application.

• Apply directly to the scalp at areas of hair thinning or loss, once or twice daily as prescribed.
• Part hair to expose scalp; apply prescribed volume and spread with fingertips.
• Wash hands thoroughly after application.
• Allow to dry fully before applying other scalp products or headwear.
• Avoid contact with eyes, face, and broken skin; rinse with water if contact occurs.

Dosing is prescriber-determined. Clinical reference points:

• Applied topically to the scalp once or twice daily (QD or BID), volume per application as specified by the prescriber.
• Consistent, uninterrupted daily use is required; benefits from both components require sustained application and are typically assessed at 3–6 months.
• Effects may persist only with continued use; discontinuation typically leads to return of hair loss over weeks to months.

• Dutasteride (0.3%): Inhibits both type 1 and type 2 5α-reductase isoenzymes, reducing intrafollicular DHT by up to 98–99%. DHT excess drives follicular miniaturization by binding androgen receptors in dermal papilla cells, shortening the anagen phase and reducing follicular diameter. Local scalp application is intended to reduce DHT at the follicle with reduced systemic exposure compared to oral dutasteride 0.5 mg/day.
• Minoxidil (8%): Opens ATP-sensitive potassium channels (KATP) in hair follicle vascular smooth muscle and follicular epithelial cells, causing local vasodilation and increased nutrient/oxygen delivery. Prolongs anagen phase, promotes follicular transition from telogen to anagen, upregulates prostaglandin E2 production, and may directly stimulate follicular dermal papilla cell proliferation.

Clinical Context: This combination is compounded for patients with androgenetic alopecia (male or female pattern hair loss) who require both DHT suppression and follicular growth stimulation. Dutasteride (oral) is superior to finasteride in clinical trials for AGA; topical use aims to deliver DHT-suppressive benefit at the scalp with reduced systemic exposure. Minoxidil (topical) is the FDA-approved standard of care for AGA and is well-established as an anagen promoter. Their combination addresses complementary pathophysiologic mechanisms.

Monitoring:

• Hair density assessment (standardized photography or trichoscopy) at 3 and 6 months.
• PSA monitoring in men — dutasteride (even topical) may reduce PSA by up to 50%; adjust prostate cancer screening interpretation.
• Assess for systemic minoxidil effects at high concentrations: heart rate, blood pressure, and peripheral edema.
• Monitor for scalp irritation and contact dermatitis.

Contraindications:

• Pregnancy and women of childbearing potential without contraception — dutasteride is Category X (teratogenic; risk of male fetal genital malformation).
• Hypersensitivity to dutasteride, minoxidil, or any excipient.
• Children: safety not established for either component in pediatric populations.

Warnings & Precautions:

• Dutasteride topical: Systemic absorption may occur; sexual side effects (decreased libido, erectile dysfunction, reduced ejaculatory volume) are less common than with oral dosing but not absent.
• Minoxidil: Scalp pruritus, contact dermatitis, initial shedding phase (first 2–8 weeks), hypertrichosis at unintended application sites. High-concentration minoxidil (8%) may have greater systemic absorption than 2–5% formulations; monitor for cardiovascular effects in susceptible patients.
• PSA: Advise prescribers to double PSA values for accurate prostate cancer screening in men receiving dutasteride-containing preparations for ≥6 months.

Drug Interactions:

• CYP3A4 inhibitors (ketoconazole, ritonavir, verapamil) may increase systemic dutasteride exposure.
• Guanethidine and other antihypertensives: additive hypotension with minoxidil.

Common Side Effects: Scalp irritation, pruritus, contact dermatitis, initial telogen effluvium-like shedding (typically resolves within 8 weeks), hypertrichosis at unintended skin sites, and possible sexual side effects from dutasteride.

Store at controlled room temperature (20–25°C / 68–77°F) unless specific vehicle requires refrigeration per pharmacy label. Protect from light, heat, and freezing. Keep container tightly closed. Store out of reach of children. Use before the beyond-use date provided by Genesis Compounding.

Why is the minoxidil concentration 8% rather than the typical 2–5%?

Higher-concentration minoxidil (6–8%) formulations are compounded when clinical judgment supports more aggressive follicular stimulation, particularly in patients with more advanced AGA or inadequate response to standard concentrations. This is a prescriber-directed decision; patients should follow their specific instructions.

How does topical dutasteride compare to oral dutasteride?

Topical application targets the scalp directly, potentially reducing DHT locally at the follicle while limiting systemic DHT suppression and associated systemic side effects (sexual dysfunction, PSA reduction). Some systemic absorption does occur, so monitoring is still appropriate. Oral dutasteride 0.5 mg achieves greater systemic DHT suppression (up to 99%).

Will I shed hair at the beginning of treatment?

An initial shedding phase of 2–8 weeks is common with minoxidil initiation, caused by synchronization of hair follicles into a new anagen cycle. This shedding is typically temporary and followed by visible regrowth. Patients should not discontinue treatment during this phase without consulting their prescriber.

Is this an FDA-approved product?

Topical minoxidil is FDA-approved for androgenetic alopecia. Topical dutasteride in this compounded formulation is an off-label use compounded by Genesis Compounding as a patient-specific 503A preparation; it is not FDA-approved as a compounded product.

How long must I use this to maintain results?

Both dutasteride and minoxidil are maintenance therapies — benefits persist only with continued use. Discontinuation typically results in return to baseline hair density within 6–12 months. Prescribers should discuss long-term use expectations at initiation.